Asunaprevir 200mg twice daily and daclatasvir 60mg once daily for 24 weeks.

2 trials

Sponsors

Saga Study Group of Liver Diseases, shonan kamakura general hospital

Conditions

Chronic hepatitis C with end-stage renal disease requiring hemodialysisChronic hepatitis C with hemodialysis

Unknown Phase

A multicenter phase II study assessed safety and efficacy of asunaprevir and daclatasvir in patients with chronic hepatitis C virus genotype 1 infection and end-stage renal disease requiring hemodialysis

Active, not recruitingJPRN-UMIN000015882

Saga Study Group of Liver DiseasesChronic hepatitis C with end-stage renal disease requiring hemodialysis

Start: 2014-12-15Target: 25Updated: 2026-06-29

Efficacy and safety of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysis

Active, not recruitingJPRN-UMIN000016181

shonan kamakura general hospitalChronic hepatitis C with hemodialysis

Start: 2015-01-14Target: 30Updated: 2026-06-29

Related Papers

Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study

Renal Replacement Therapy2017-01-132 citations